SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881107081562v1
22/5/581    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kotzalidis, G.
Right arrow Articles by Girardi, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kotzalidis, G.
Right arrow Articles by Girardi, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Similar discontinuation symptoms for withdrawal from medium-dose paroxetine and venlafaxine after nine years in the same patient

GD Kotzalidis

Department of Neurosciences, Psychiatry Unit, Sapienza University, 2nd Medical School, Sant'Andrea Hospital, Rome, Italy, giorgio.kotzalidis{at}uniroma1.it

E. de Pisa

Department of Neurosciences, Psychiatry Unit, Sapienza University, 2nd Medical School, Sant'Andrea Hospital, Rome, Italy

B. Patrizi

Department of Neurosciences, Psychiatry Unit, Sapienza University, 2nd Medical School, Sant'Andrea Hospital, Rome, Italy

V. Savoja

Department of Neurosciences, Psychiatry Unit, Sapienza University, 2nd Medical School, Sant'Andrea Hospital, Rome, Italy

G. Ruberto

Department of Neurosciences, Psychiatry Unit, Sapienza University, 2nd Medical School, Sant'Andrea Hospital, Rome, Italy

P. Girardi

Department of Neurosciences, Psychiatry Unit, Sapienza University, 2nd Medical School, Sant'Andrea Hospital, Rome, Italy

A woman who had developed a discontinuation syndrome nine years ago with paroxetine tapered from 10 to 5 mg/day represented the same syndrome recently when she occasionally missed her 75 mg q 12 h venlafaxine doses. The symptoms, comprising agitation, numbness, pricking sensations, sweating, difficulty concentrating, weakness, derealisation and perceived xerophthalmia, immediately subside upon drug dose reinstitution. The patient had used cannabis irregularly before the onset of pauci-symptomatic panic attacks, but none of her panic symptoms were present in her withdrawal symptomatology. Some symptoms waxed and waned during the withdrawal period. The syndrome is compatible with both hyper- and hypoactivity of the central serotonergic system.

Key Words: selective-serotonin re-uptake inhibitors • discontinuation syndrome • paroxetine • venlafaxine • dry eye (xerophthalmia) • cannabis use • cross-sensitisation

This version was published on July 1, 2008

Journal of Psychopharmacology, Vol. 22, No. 5, 581-584 (2008)
DOI: 10.1177/0269881107081562
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement